罗氟司特
支气管扩张剂联合ICS
免疫调节剂
黏液调节剂
抗感染治疗
参考资料:
1.Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2022 Report.DOI: 10.12114/j.issn.1007-9572.2022.01.302
2.中国慢性阻塞性肺疾病急性加重中西医诊治专家共识(2021)[J].中华危重病急救医学,2021,33(11):1281-1290.
3.Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease. Lung. 2015 Aug;193(4):513-9. doi: 10.1007/s00408-015-9737-3.
4.Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine,and N-acetylcysteine [J]. Respir Res, 2019, 20 (1): 104. DOI:10.1186/s12931-019-1078-y
5.AECOPD抗感染治疗策略新进展.https://cn.infectweb.com/articles/1129.html
6.Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations:a systematic review and meta-analysis[J]. Infect Dis,2019,51(9):639-650.
作者 | 图图
编辑 | 权
联系客服